ERAS
Erasca, Inc.
Biotechnology
Market Cap$3.09B
5Y Perf.-48.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ERAS vs RVMD
Revenue, margins, valuation, and 5-year total return — side by side.
RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$32.12B
5Y Perf.+427.5%
ERAS vs RVMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ERAS | RVMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.09B | $32.12B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-128M | $-1.37B |
| Total Debt | $52M | $159M |
| Cash & Equiv. | $68M | $384M |
ERAS vs RVMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ERAS
RVMD
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 100 | 51.9 | -48.1% |
| Revolution Medicine… (RVMD) | 100 | 527.5 | +427.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ERAS vs RVMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ERAS leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ERAS
Erasca, Inc.
The Income Pick
ERAS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.78
- EPS growth 16.9%
- Lower volatility, beta 0.78, Low D/E 12.3%, current ratio 9.84x
Best for: income & stability and growth exposure
RVMD
Revolution Medicines, Inc.
The Long-Run Compounder
RVMD is the clearest fit if your priority is long-term compounding.
- 422.7% 10Y total return vs ERAS's -37.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ERAS | 19.8% revenue growth vs RVMD's -98.6% |
| Quality / Margins | ERAS | 4.0% margin vs RVMD's 2.8% |
| Stability / Safety | ERAS | Beta 0.78 vs RVMD's 1.08 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ERAS | +7.7% vs RVMD's +303.5% |
| Efficiency (ROA) | ERAS | -30.4% ROA vs RVMD's -59.1%, ROIC -39.2% vs -54.3% |
ERAS vs RVMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
ERAS vs RVMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLERASLAGGINGRVMD
RVMDRevolution Medicines,…
1leads
ERASErasca, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RVMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ERAS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ERAS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ERAS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ERAS and RVMD operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ERASErasca, Inc. | RVMDRevolution Medici… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$141M | -$1.4B |
| Net IncomeAfter-tax profit | -$128M | -$1.4B |
| Free Cash FlowCash after capex | -$98M | -$1.1B |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | -102.7% |
ERAS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ERAS and RVMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ERASErasca, Inc. | RVMDRevolution Medici… |
|---|---|---|
| Market CapShares × price | $3.1B | $32.1B |
| Enterprise ValueMkt cap + debt − cash | $3.1B | $31.9B |
| Trailing P/EPrice ÷ TTM EPS | -15.80x | -25.39x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.02x | 17.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ERAS and RVMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ERAS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
ERAS delivers a -36.7% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-83 for RVMD. RVMD carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to ERAS's 0.12x. On the Piotroski fundamental quality scale (0–9), ERAS scores 2/9 vs RVMD's 1/9, reflecting mixed financial health.
| Metric | ERASErasca, Inc. | RVMDRevolution Medici… |
|---|---|---|
| ROE (TTM)Return on equity | -36.7% | -83.2% |
| ROA (TTM)Return on assets | -30.4% | -59.1% |
| ROICReturn on invested capital | -39.2% | -54.3% |
| ROCEReturn on capital employed | -42.7% | -53.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.12x | 0.10x |
| Net DebtTotal debt minus cash | -$16M | -$225M |
| Cash & Equiv.Liquid assets | $68M | $384M |
| Total DebtShort + long-term debt | $52M | $159M |
| Interest CoverageEBIT ÷ Interest expense | — | -81.62x |
ERAS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RVMD five years ago would be worth $52,093 today (with dividends reinvested), compared to $6,254 for ERAS. Over the past 12 months, ERAS leads with a +772.0% total return vs RVMD's +303.5%. The 3-year compound annual growth rate (CAGR) favors RVMD at 83.5% vs ERAS's 56.2% — a key indicator of consistent wealth creation.
| Metric | ERASErasca, Inc. | RVMDRevolution Medici… |
|---|---|---|
| YTD ReturnYear-to-date | +203.6% | +91.2% |
| 1-Year ReturnPast 12 months | +772.0% | +303.5% |
| 3-Year ReturnCumulative with dividends | +281.1% | +518.1% |
| 5-Year ReturnCumulative with dividends | -37.5% | +420.9% |
| 10-Year ReturnCumulative with dividends | -37.5% | +422.7% |
| CAGR (3Y)Annualised 3-year return | +56.2% | +83.5% |
RVMD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ERAS and RVMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
ERAS is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than RVMD's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 97.0% from its 52-week high vs ERAS's 44.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ERASErasca, Inc. | RVMDRevolution Medici… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 1.08x |
| 52-Week HighHighest price in past year | $24.28 | $155.70 |
| 52-Week LowLowest price in past year | $1.06 | $34.00 |
| % of 52W HighCurrent price vs 52-week peak | +44.9% | +97.0% |
| RSI (14)Momentum oscillator 0–100 | 33.2 | 64.2 |
| Avg Volume (50D)Average daily shares traded | 7.0M | 3.0M |
Evenly matched — ERAS and RVMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ERAS as "Buy" and RVMD as "Buy". Consensus price targets imply 24.8% upside for ERAS (target: $14) vs 2.5% for RVMD (target: $155).
| Metric | ERASErasca, Inc. | RVMDRevolution Medici… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $13.60 | $154.80 |
| # AnalystsCovering analysts | 11 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ERAS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RVMD leads in 1 (Total Returns). 2 tied.
Best OverallErasca, Inc. (ERAS)Leads 2 of 6 categories
Loading custom metrics...
ERAS vs RVMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ERAS or RVMD a better buy right now?
Analysts rate Erasca, Inc.
(ERAS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ERAS or RVMD?
Over the past 5 years, Revolution Medicines, Inc.
(RVMD) delivered a total return of +420. 9%, compared to -37. 5% for Erasca, Inc. (ERAS). Over 10 years, the gap is even starker: RVMD returned +422. 7% versus ERAS's -37. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ERAS or RVMD?
By beta (market sensitivity over 5 years), Erasca, Inc.
(ERAS) is the lower-risk stock at 0. 78β versus Revolution Medicines, Inc. 's 1. 08β — meaning RVMD is approximately 39% more volatile than ERAS relative to the S&P 500. On balance sheet safety, Revolution Medicines, Inc. (RVMD) carries a lower debt/equity ratio of 10% versus 12% for Erasca, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ERAS or RVMD?
On earnings-per-share growth, the picture is similar: Erasca, Inc.
grew EPS 16. 9% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ERAS or RVMD?
Erasca, Inc.
(ERAS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Revolution Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ERAS leads at 0. 0% versus 0. 0% for RVMD. At the gross margin level — before operating expenses — ERAS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ERAS or RVMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ERAS or RVMD better for a retirement portfolio?
For long-horizon retirement investors, Revolution Medicines, Inc.
(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +422. 7% 10Y return). Both have compounded well over 10 years (RVMD: +422. 7%, ERAS: -37. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ERAS and RVMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.